Your browser doesn't support javascript.
loading
HIV care in Central and Eastern Europe: How close are we to the target?
Gokengin, Deniz; Oprea, Cristiana; Begovac, Josip; Horban, Andrzej; Zeka, Arzu Nazli; Sedlacek, Dalibor; Allabergan, Bayjanov; Almamedova, Esmira A; Balayan, Tatevik; Banhegyi, Denes; Bukovinova, Pavlina; Chkhartishvili, Nikoloz; Damira, Alymbaeva; Deva, Edona; Elenkov, Ivaylo; Gashi, Luljeta; Gexha-Bunjaku, Dafina; Hadciosmanovic, Vesna; Harxhi, Arjan; Holban, Tiberiu; Jevtovic, Djorje; Jilich, David; Kowalska, Justyna; Kuvatova, Djhamal; Ladnaia, Natalya; Mamatkulov, Adkhamjon; Marjanovic, Aleksandra; Nikolova, Maria; Poljak, Mario; Rüütel, Kristi; Shunnar, Azzaden; Stevanovic, Milena; Trumova, Zhanna; Yurin, Oleg.
Afiliación
  • Gokengin D; Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Ege University Izmir, Turkey. Electronic address: deniz.gokengin@ege.edu.tr.
  • Oprea C; 'Victor Babes' Clinical Hospital for Infectious and Tropical Diseases, 'Carol Davila' University of Medicine and Pharmacy, Bucharest, Romania.
  • Begovac J; University of Zagreb School of Medicine, University Hospital for Infectious Diseases, Zagreb, Croatia.
  • Horban A; Hospital for Infectious Diseases in Warsaw, Medical University of Warsaw, Warsaw, Poland.
  • Zeka AN; Yunus Emre State Hospital, Eskisehir, Turkey.
  • Sedlacek D; Department of Infectious and Travellers Diseases, Charles University Medical Faculty, Pilsen, Czech Republic.
  • Allabergan B; Institute of Virology, Ministry of Public Health of Uzbekistan, Tashkent, Uzbekistan.
  • Almamedova EA; AIDS Control Centre, Baku, Azerbaijan.
  • Balayan T; National Centre for Disease Control and Prevention of Armenia, Yerevan, Armenia.
  • Banhegyi D; Szent Laszlo Hospital, Budapest, Hungary.
  • Bukovinova P; Centre for HIV/AIDS, Clinic of Infectious Diseases, University Hospital, Bratislava, Slovakia.
  • Chkhartishvili N; Infectious Diseases, AIDS and Clinical Immunology Research Centre, Tbilisi, Georgia.
  • Damira A; Department of Infectious Diseases, Division of Medicine, Kyrgyz-Russian Slavonic University, Bishkek, Kyrgyzstan.
  • Deva E; Community Development Fund, Prishtina, Kosovo.
  • Elenkov I; Specialized Hospital for Active Treatment of Infectious and Parasitic Diseases, Sofia, Bulgaria.
  • Gashi L; National Institute of Public Health of Kosovo, Prishtina, Kosovo.
  • Gexha-Bunjaku D; National Institute of Public Health of Kosovo, Prishtina, Kosovo.
  • Hadciosmanovic V; Clinical Centre, Infectious Diseases Clinic, University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
  • Harxhi A; Infectious Disease Department, Faculty of Medicine, University Hospital Centre of Tirana, Tiran, Albania.
  • Holban T; State Medical and Pharmaceutical University Nicolae Testemitanu, Department of Infectious Diseases and Medical Parasitology, Chisinau, Republic of Moldova.
  • Jevtovic D; University of Belgrade School of Medicine, Infectious and Tropical Diseases Hospital, Clinical Centre Serbia, HIV/AIDS Unit, Belgrade, Serbia.
  • Jilich D; Department of Infectious and Tropical Diseases, First Faculty of Medicine, Charles University and Na Bulovce Hospital, Prague, Czech Republic.
  • Kowalska J; Hospital for Infectious Diseases in Warsaw, Medical University of Warsaw, Warsaw, Poland.
  • Kuvatova D; Department of Infectious Diseases, Division of Medicine, Kyrgyz-Russian Slavonic University, Bishkek, Kyrgyzstan.
  • Ladnaia N; Central Scientific Research Institute of Epidemiology of Rospotrebnadzor, Russian Federal AIDS Centre, Moscow, Russian Federation.
  • Mamatkulov A; Institute of Virology, Ministry of Public Health of Uzbekistan, Tashkent, Uzbekistan.
  • Marjanovic A; Institute of Public Health, Podgorica, Montenegro.
  • Nikolova M; National Reference Laboratory of Immunology, National Centre of Infectious and Parasitic Diseases, Sofia, Bulgaria.
  • Poljak M; Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
  • Rüütel K; National Institute for Health Development, Tallinn, Estonia.
  • Shunnar A; Centre for HIV/AIDS, Clinic of Infectious Diseases, University Hospital, Bratislava, Slovakia.
  • Stevanovic M; Clinic for Infectious Diseases and Febrile Conditions, Skopje, Former Yugoslav Republic of Macedonia.
  • Trumova Z; Department of HIV Infection and Infection Control, Kazakh National Medical University, Almaty, Kazakhstan.
  • Yurin O; Central Scientific Research Institute of Epidemiology of Rospotrebnadzor, Russian Federal AIDS Centre, Moscow, Russian Federation.
Int J Infect Dis ; 70: 121-130, 2018 May.
Article en En | MEDLINE | ID: mdl-29550449
ABSTRACT

OBJECTIVES:

The aim of this survey was to describe the current status of HIV care in the countries of Central and Eastern Europe and to investigate how close the region is to achieving the UNAIDS 2020 target of 90-90-90.

METHODS:

In 2014, data were collected from 24 Central and Eastern European countries using a 38-item questionnaire.

RESULTS:

All countries reported mandatory screening of blood and organ donors for HIV. Other groups subjected to targeted screening included people who inject drugs (PWID) (15/24, 62.5%), men who have sex with men (MSM) (14/24, 58.3%), and sex workers (12/24, 50.0%). Only 14 of the 24 countries (58.3%) screened pregnant women. The percentages of late presentation and advanced disease were 40.3% (range 14-80%) and 25.4% (range 9-50%), respectively. There was no difference between countries categorized by income or by region in terms of the percentages of persons presenting late or with advanced disease. The availability of newer antiretroviral drugs (rilpivirine, etravirine, darunavir, maraviroc, raltegravir, dolutegravir) tended to be significantly better with a higher country income status. Ten countries reported initiating antiretroviral therapy (ART) regardless of CD4+ T cell count (41.7%), five countries (20.8%) used the threshold of <500 cells/µl, and nine countries (37.5%) used the threshold of <350cells/µl. Initiation of ART regardless of the CD4+ T cell count was significantly more common among high-income countries than among upper-middle-income and lower-middle-income countries (100% vs. 27.3% and 0%, respectively; p=0.001). Drugs were provided free of charge in all countries and mostly provided by governments. There were significant discrepancies between countries regarding the follow-up of people living with HIV.

CONCLUSIONS:

There are major disparities in the provision of HIV care among sub-regions in Europe, which should be addressed. More attention in terms of funding, knowledge and experience sharing, and capacity building is required for the resource-limited settings of Central and Eastern Europe. The exact needs should be defined and services scaled up in order to achieve a standard level of care and provide an adequate and sustainable response to the HIV epidemic in this region.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones por VIH Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Int J Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2018 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones por VIH Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Int J Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2018 Tipo del documento: Article
...